Qiagen N.v.
QGEN NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 30, 2026
$50.22
KIRA · Stoqly’s AI analyst, in plain words
- Qiagen N.v. had $2.1B of revenue in fiscal 2025, up 5.7% on the year before. Over five years, revenue changed +2.2% a year on average.
- Its operating margin was 22.3%, up 17.4 pts: of every 100 in sales, about 22 is left after running the business.
- Qiagen N.v. made $425M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 21.3% a year.
- Free cash flow was $453M in fiscal 2025, 21.7% of revenue.
- Qiagen N.v. returned $334M to shareholders in fiscal 2025, 74% of free cash flow. The diluted share count fell 2.6%.
- Qiagen N.v. owes $556M more than it holds in cash, about 0.8 years of operating profit.
Market cap
$11.0B
P/E
25.9x
Revenue
$2.1B
Net income
$425M
Free cash flow
$453M
Operating margin
22.3%
Qiagen N.v. in 30 seconds · fiscal 2025
Are sales growing?
+5.7%
Yes. Sales grew 5.7% last year.
Does it make a profit?
20.3%
Yes. It keeps 20.3% of every sale as profit.
Does profit turn into cash?
21.7%
Yes. 21.7% of sales ends up as free cash.
Is debt under control?
0.8x
Yes. It could repay its debt with 0.8 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
25.9x
One share costs 25.9 times its yearly profit per share.
What Qiagen N.v. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 20, 2026
- Legal name
- QIAGEN N.V.
- CIK
- 0001015820
Qiagen N.v. · QGEN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.3B | $2.1B | $2.0B | $2.0B | $2.1B |
| Revenue growth | 20.4% | −4.9% | −8.2% | 0.7% | 5.7% |
| Gross margin | 64.4% | 64.7% | 62.8% | 48.9% | 62.2% |
| Operating margin | 28.0% | 24.8% | 20.9% | 4.9% | 22.3% |
| Net income | $513M | $423M | $341M | $83.6M | $425M |
| Net margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| Diluted EPS | $2.21 | $1.84 | $1.48 | $0.37 | $1.94 |
| Cash | |||||
| Cash from operations | $639M | $715M | $459M | $674M | $654M |
| Capital expenditure | $190M | $129M | $150M | $167M | $201M |
| Free cash flow | $449M | $586M | $310M | $506M | $453M |
| FCF margin | 19.9% | 27.4% | 15.8% | 25.6% | 21.7% |
| Dividends paid | — | — | $0.0M | $0.0M | $54.2M |
| Share buybacks | $100.0M | $0.0M | $0.0M | $292M | $280M |
| Share count change | −0.9% | −0.8% | 0.2% | −2.6% | −2.6% |
| Debt and strength | |||||
| Cash and short-term investments | $1.1B | $1.4B | $1.1B | $1.2B | $1.1B |
| Debt incl. finance leases | $1.9B | $1.9B | $1.5B | $1.4B | $1.7B |
| Shareholders' equity | $3.1B | $3.5B | $3.8B | $3.6B | $3.8B |
| Net debt / EBITDA | 1.0x | 0.6x | 0.7x | 0.8x | 0.8x |
| Current ratio | 1.4x | 2.5x | 2.0x | 1.9x | 3.9x |
| Interest coverage | 11.6x | 9.1x | 7.7x | 2.2x | 14.0x |
| Returns and quality | |||||
| Return on capital | 13.0% | 11.2% | 7.6% | 1.8% | 9.3% |
| Return on equity | 17.4% | 12.9% | 9.4% | 2.3% | 11.6% |
| Return on tangible equity | 433.1% | 74.3% | 42.4% | 10.0% | 61.5% |
| Piotroski F-score | 7 | 7 | 4 | 6 | 7 |
| Altman Z'' | 3.3 | 4.5 | 4.6 | 4.3 | 5.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Qiagen N.v. · QGEN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $50.22 a share, the company is worth $11.0B: 25.9 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001015820). Latest version: stoqly.net/companies/qgen. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.